Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.

Burghard MM, Berkers GG, Ghijsen SS, Hollander-Kraaijeveld FF, de Winter-de Groot KK, van der Ent CK, Heijerman HH, Takken TT, Hulzebos HE.

Pediatr Pulmonol. 2020 Mar 31. doi: 10.1002/ppul.24745. [Epub ahead of print]

PMID:
32233113
2.

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?

van Maarseveen EM, van der Meer R, Neef C, Heijerman HGM, Touw DJ.

Ther Drug Monit. 2020 Feb 11. doi: 10.1097/FTD.0000000000000743. [Epub ahead of print]

PMID:
32049889
3.

Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline.

Aalbers BL, de Winter-de Groot KM, Arets HGM, Hofland RW, de Kiviet AC, van Oirschot-van de Ven MMM, Kruijswijk MA, Schotman S, Michel S, van der Ent CK, Heijerman HGM.

J Cyst Fibros. 2020 Jan 7. pii: S1569-1993(19)30995-6. doi: 10.1016/j.jcf.2019.12.015. [Epub ahead of print]

PMID:
31924546
4.

Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.

de Winter-de Groot KM, Berkers G, Marck-van der Wilt REP, van der Meer R, Vonk A, Dekkers JF, Geerdink M, Michel S, Kruisselbrink E, Vries R, Clevers H, Vleggaar FP, Elias SG, Heijerman HGM, van der Ent CK, Beekman JM.

J Cyst Fibros. 2019 Nov 14. pii: S1569-1993(19)30937-3. doi: 10.1016/j.jcf.2019.10.022. [Epub ahead of print]

PMID:
31735562
5.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group.

Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.

PMID:
31679946
6.

Prevention of drug-related complications in cystic fibrosis.

van der Meer R, Touw DJ, Heijerman HGM.

Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625.

PMID:
31503211
7.

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough.

Meerburg JJ, Albasri M, van der Wiel EC, Andrinopoulou ER, van der Eerden MM, Majoor CJ, Arets HGM, Heijerman HGM, Tiddens HAWM.

Pediatr Pulmonol. 2019 Nov;54(11):1794-1800. doi: 10.1002/ppul.24467. Epub 2019 Aug 8.

8.

Non-fasting bioelectrical impedance analysis in cystic fibrosis: Implications for clinical practice and research.

Hollander-Kraaijeveld FM, Lindeman Y, de Roos NM, Burghard M, van de Graaf EA, Heijerman HGM.

J Cyst Fibros. 2020 Jan;19(1):153-158. doi: 10.1016/j.jcf.2019.05.018. Epub 2019 Jun 5.

PMID:
31176668
9.

Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration.

Post TE, Kamerling IMC, van Rossen RCJM, Burggraaf J, Stevens J, Dijkmans AC, Heijerman HGM, Touw DJ, van Velzen AJ, Wilms EB.

Eur J Hosp Pharm. 2018 Nov;25(6):337-339. doi: 10.1136/ejhpharm-2016-001128. Epub 2017 Mar 18.

10.

Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.

van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, van Maarseveen EM, van Zanten GA, Pullens B, Touw DJ, Janssens HM.

Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10.

11.

Aligning patients' needs and research priorities towards a comprehensive CF research program.

Noordhoek JJ, Gulmans VAM, Heijerman HGM, van der Ent CK.

J Cyst Fibros. 2019 May;18(3):382-384. doi: 10.1016/j.jcf.2019.03.008. Epub 2019 Mar 26.

PMID:
30926323
12.

Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.

Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de Jonge HR, Beekman JM, van der Ent CK.

Cell Rep. 2019 Feb 12;26(7):1701-1708.e3. doi: 10.1016/j.celrep.2019.01.068.

13.

Authors' response: Letter to the Editor 'Anaemia and iron deficiency in relation to fatigue in cystic fibrosis'.

Nap-van der Vlist MM, Burghard M, Hulzebos HJ, Doeleman WR, Heijerman HGM, van der Ent CK, Nijhof SL.

J Cyst Fibros. 2019 Jan;18(1):e6-e7. doi: 10.1016/j.jcf.2018.10.002. Epub 2018 Oct 12. No abstract available.

PMID:
30318450
14.

Prevalence of severe fatigue among adults with cystic fibrosis: A single center study.

Nap-van der Vlist MM, Burghard M, Hulzebos HJ, Doeleman WR, Heijerman HGM, van der Ent CK, Nijhof SL.

J Cyst Fibros. 2018 May;17(3):368-374. doi: 10.1016/j.jcf.2018.03.003. Epub 2018 Mar 29.

PMID:
29606526
15.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

16.

Specific airway resistance is a better outcome parameter in bronchial provocation testing compared to FEV1 in patients with bronchial asthma.

van Nederveen-Bendien SA, Vahl J, Heijerman HGM.

J Asthma. 2018 Dec;55(12):1338-1342. doi: 10.1080/02770903.2017.1414238. Epub 2018 Jan 17.

PMID:
29341788
17.

The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendations.

Hollander FM, de Roos NM, Heijerman HGM.

Curr Opin Pulm Med. 2017 Nov;23(6):556-561. doi: 10.1097/MCP.0000000000000430. Review.

PMID:
28991007
18.

Body Weight and Body Mass Index in Patients with End-Stage Cystic Fibrosis Stabilize After the Start of Enteral Tube Feeding.

Hollander FM, de Roos NM, Belle van Meerkerk G, Teding van Berkhout F, Heijerman HGM, van de Graaf EA.

J Acad Nutr Diet. 2017 Nov;117(11):1808-1815. doi: 10.1016/j.jand.2017.07.006. Epub 2017 Sep 12.

PMID:
28919081
19.

β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.

Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28.

20.

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.

Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM.

Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278.

PMID:
27334259
21.

The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients.

van Mansfeld R, de Vrankrijker A, Brimicombe R, Heijerman H, Teding van Berkhout F, Spitoni C, Grave S, van der Ent C, Wolfs T, Willems R, Bonten M.

PLoS One. 2016 Jun 9;11(6):e0157189. doi: 10.1371/journal.pone.0157189. eCollection 2016.

22.

CT-abnormalities, bacteriology and symptoms of sinonasal disease in children with Cystic Fibrosis.

Berkhout MC, Klerx-Melis F, Fokkens WJ, Nuijsink M, van Aalderen WM, Heijerman HG.

J Cyst Fibros. 2016 Nov;15(6):816-824. doi: 10.1016/j.jcf.2016.03.004. Epub 2016 Apr 3.

23.

Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.

van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HG, Janssens HM.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80. doi: 10.1089/jamp.2015.1259. Epub 2015 Dec 30.

PMID:
26716357
24.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

25.

The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.

van Velzen AJ, Uges JW, Le Brun PP, Shahbabai P, Touw DJ, Heijerman HG.

J Cyst Fibros. 2015 Nov;14(6):748-54. doi: 10.1016/j.jcf.2015.01.002. Epub 2015 Jan 27.

26.

JCF - 2014 and beyond.

Bell SC, Heijerman H, Hartl D.

J Cyst Fibros. 2014 Dec;13(6):610-1. doi: 10.1016/j.jcf.2014.09.009. Epub 2014 Nov 8. No abstract available.

27.

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.

Vreede CL, Berkhout MC, Sprij AJ, Fokkens WJ, Heijerman HG.

J Cyst Fibros. 2015 May;14(3):412-3. doi: 10.1016/j.jcf.2014.07.013. Epub 2014 Aug 26.

28.

Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis.

Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG.

J Antimicrob Chemother. 2014 Nov;69(11):3112-5. doi: 10.1093/jac/dku239. Epub 2014 Jul 11.

PMID:
25016384
29.

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D.

J Cyst Fibros. 2014 May;13 Suppl 1:S3-22. doi: 10.1016/j.jcf.2014.03.009. Review.

30.

Temporal bone pneumatization in cystic fibrosis: a correlation with genotype?

Berkhout MC, van Rooden CJ, Aalbers RC, el Bouazzaoui LH, Fokkens WJ, Rijntjes E, Heijerman HG.

Laryngoscope. 2014 Jul;124(7):1682-6. doi: 10.1002/lary.24575. Epub 2014 Feb 6.

PMID:
24374715
31.

Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype?

Berkhout MC, van Rooden CJ, Rijntjes E, Fokkens WJ, el Bouazzaoui LH, Heijerman HG.

J Cyst Fibros. 2014 Jul;13(4):442-8. doi: 10.1016/j.jcf.2013.10.011. Epub 2013 Nov 5.

32.

Importance of bacteriology in upper airways of patients with Cystic Fibrosis.

Berkhout MC, Rijntjes E, El Bouazzaoui LH, Fokkens WJ, Brimicombe RW, Heijerman HG.

J Cyst Fibros. 2013 Sep;12(5):525-9. doi: 10.1016/j.jcf.2013.01.002. Epub 2013 Jan 26.

33.

Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group.

J Cyst Fibros. 2012 Dec;11(6):461-79. doi: 10.1016/j.jcf.2012.10.004. Epub 2012 Nov 6. Review.

34.

Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects.

Wilms EB, Touw DJ, Heijerman HG, van der Ent CK.

Pediatr Pulmonol. 2012 Jul;47(7):658-65. doi: 10.1002/ppul.21620. Epub 2012 Jan 3. Review.

PMID:
22684985
35.

Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case-control study.

Verregghen M, Heijerman HG, Reijers M, van Ingen J, van der Ent CK.

J Cyst Fibros. 2012 Jul;11(4):340-3. doi: 10.1016/j.jcf.2012.01.006. Epub 2012 Feb 18.

36.

Clinical impact of a highly prevalent Pseudomonas aeruginosa clone in Dutch cystic fibrosis patients.

de Vrankrijker AM, Brimicombe RW, Wolfs TF, Heijerman HG, van Mansfeld R, van Berkhout FT, Willems RJ, Bonten MJ, van der Ent CK.

Clin Microbiol Infect. 2011 Mar;17(3):382-5. doi: 10.1111/j.1469-0691.2010.03295.x. Epub 2010 Aug 30.

37.

Long-term effects of birth order and age at diagnosis in cystic fibrosis: a sibling cohort study.

Slieker MG, van den Berg JM, Kouwenberg J, van Berkhout FT, Heijerman HG, van der Ent CK.

Pediatr Pulmonol. 2010 Jun;45(6):601-7. doi: 10.1002/ppul.21227.

PMID:
20503286
38.

Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients and age dependency of colonization by various P. aeruginosa sequence types.

van Mansfeld R, Willems R, Brimicombe R, Heijerman H, van Berkhout FT, Wolfs T, van der Ent C, Bonten M.

J Clin Microbiol. 2009 Dec;47(12):4096-101. doi: 10.1128/JCM.01462-09. Epub 2009 Oct 14. Erratum in: J Clin Microbiol. 2013 Jan;51(1):386.

39.

A productive cough.

Schild D, Heijerman HG, Sleeboom HP.

Neth J Med. 2009 Apr;67(4):154-5. No abstract available.

40.

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group.

J Cyst Fibros. 2009 Sep;8(5):295-315. doi: 10.1016/j.jcf.2009.04.005. Epub 2009 Jun 25. Review.

41.

No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.

Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E.

Acta Otolaryngol. 2010 Feb;130(2):253-8. doi: 10.3109/00016480903015150.

PMID:
19479457
42.

Demographics of glucose metabolism in cystic fibrosis.

van den Berg JM, Kouwenberg JM, Heijerman HG.

J Cyst Fibros. 2009 Jul;8(4):276-9. doi: 10.1016/j.jcf.2009.04.010. Epub 2009 May 24.

43.

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.

Rottier BL, van Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, Boer AH.

J Aerosol Med Pulm Drug Deliv. 2009 Sep;22(3):263-9. doi: 10.1089/jamp.2008.0712.

PMID:
19466906
44.

Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.

Westerman EM, Boer AH, Touw DJ, Brun PP, Roldaan AC, Frijlink HW, Heijerman HG.

J Aerosol Med Pulm Drug Deliv. 2008 Sep;21(3):269-80. doi: 10.1089/jamp.2007.0674.

PMID:
18759658
45.

Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).

van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG.

J Cyst Fibros. 2008 Nov;7(6):515-9. doi: 10.1016/j.jcf.2008.05.008. Epub 2008 Jul 11.

46.

Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.

Scheenstra RJ, Rijntjes E, Tavy DL, Kingma H, Heijerman HG.

Acta Otolaryngol. 2009 Jan;129(1):4-7. doi: 10.1080/00016480801968534.

PMID:
18607923
47.

CFTR mutations in Turkish and North African cystic fibrosis patients in Europe: implications for screening.

Lakeman P, Gille JJ, Dankert-Roelse JE, Heijerman HG, Munck A, Iron A, Grasemann H, Schuster A, Cornel MC, Ten Kate LP.

Genet Test. 2008 Mar;12(1):25-35. doi: 10.1089/gte.2007.0046.

PMID:
18373402
48.

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.

Wilms EB, Touw DJ, Heijerman HG.

J Cyst Fibros. 2008 Jan;7(1):79-84. Epub 2007 Jun 27.

49.

Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Vinks AA, van Rossem RN, Mathôt RA, Heijerman HG, Mouton JW.

Antimicrob Agents Chemother. 2007 Sep;51(9):3049-55. Epub 2007 Jun 18.

50.

Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands.

Brimicombe RW, Dijkshoorn L, van der Reijden TJ, Kardoes I, Pitt TL, van den Broek PJ, Heijerman HG.

J Cyst Fibros. 2008 Jan;7(1):30-6. Epub 2007 May 25.

Supplemental Content

Loading ...
Support Center